PlumX Metrics
Embed PlumX Metrics

Novel Therapies for Blastic Plasmacytoid Dendritic Cell Neoplasm

Hematology/Oncology Clinics of North America, ISSN: 0889-8588, Vol: 34, Issue: 3, Page: 589-600
2020
  • 17
    Citations
  • 0
    Usage
  • 16
    Captures
  • 0
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

Review Description

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an orphan hematologic malignancy with poor outcomes. Tagraxofusp (SL-401) was the first drug approved specifically for patients with BPDCN, in 2018. Additional therapeutic strategies are still needed to improve survival and minimize treatment-related toxicity. This article outlines novel targeted approaches that are in preclinical or clinical development for BPDCN. Although there is no known targetable genetic abnormality that defines BPDCN, data from functional testing of primary tumors, gene expression analyses, and adaptation of targeted drug approaches from other cancers to BPDCNs harboring specific mutations have nominated several promising strategies.

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know